BioTime, Inc.

BioTime, Inc.

Sector: Biological Products Except Diagnostic Substances Region: CA, United States


BioTime is a biotechnology company focused on the emerging field of regenerative medicine. Our core technologies center on pluripotent stem cells that are capable of becoming all of the cell types in the human body. Products made from these stem cells are being developed by our subsidiaries, each of which concentrates on different medical specialties, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. BioTime’s commercial strategy targets near-term yet strategic commercial opportunities such as: Renevia (a product currently in clinical trials in Europe to facilitate cell transplantation); ReGlyde and Premvia for tendon and dermatological applications; PanC-Dx (a family of novel blood-based cancer screens); our current line of research products including PureStem cell lines, associated ESpan culture media, and GMP-capable human embryonic stem cell lines; and the LifeMap Database Suite. Cellular therapeutics in development include: OpRegen (hESC-derived RPE cells for the treatment of macular degeneration); OPC1 (hESC-derived oligodendrocyte progenitors for spinal cord injury); and VAC1 (a dendritic cell-based vaccine for cancer based on the telomerase antigen).


Michael D. West, Ph.D., Chief Executive Officer
Michael D. West, Ph.D. became our Chief Executive Officer during October 2007, and has served on the Board of Directors since 2002. Prior to becoming our Chief Executive Officer, Dr. West served as Chief Executive Officer, President, and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Dr. West also founded Geron Corporation of Menlo Park, California, and from 1990 to 1998 he was a Director and Vice-President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.
Robert W. Peabody, Senior VP , Chief Operating Officer and Chief Financial Officer
Robert W. Peabody is our Senior Vice-President, Chief Operating Officer, and Chief Financial Officer. Mr. Peabody has served as our Senior Vice-President and Chief Operating Officer since 2007, and also served on an interim basis as our Chief Financial Officer from September 2010 until October 2011 before reassuming the role in May 2013. Prior to joining BioTime in October 2007, Mr. Peabody served as a Vice-President of Advanced Cell Technology, Inc., and also served on their board of directors from 1998 to 2006. Prior to joining ACT, Mr. Peabody spent 14 years as a Regional Controller for Ecolab, Inc., a Fortune 500 specialty chemical manufacturer and service company. He has also been an audit manager for Ernst and Young where he was a Certified Public Accountant on the audit staff serving the firm’s clients whose shares are publicly traded. Mr. Peabody received a Bachelor Degree in Business Administration from the University of Michigan.
William P. Tew, Ph.D. , Chief Commercial Officer
William P. Tew, Ph.D. was appointed our Chief Commercial Officer in June 2011. Before joining BioTime, Dr. Tew was co-founder, President, and Chief Executive Officer of Glycosan BioSystems, Inc., which was acquired by BioTime’s subsidiary OrthoCyte Corporation in 2011. Dr. Tew founded Glycosan in 2006 and oversaw Glycosan’s development and commercialization of an array of hydrogel extracellular matrix products, generating growing revenues and building a substantial base of customers at leading research universities. In 1980, Dr. Tew founded Chesapeake Biological Laboratories (CBL), where he served as chairman and CEO for almost two decades (1981-1999), developing and manufacturing bulk pharmaceuticals, parenteral drugs, and medical devices in compliance with FDA regulations. CBL’s revenues and profits grew steadily under Dr. Tew’s leadership and the Company was acquired by Cangene Corporation for $42 million in 2001.
Hal Sternberg, Ph.D. , Vice President of Research
Hal Sternberg, Ph.D. has been our Vice President of Research since 1990 and is one of the co-founders of BioTime. Dr. Sternberg was a visiting scientist and research Associate at the University of California at Berkeley from 1985-1988, where he supervised a team of researchers studying Alzheimer’s Disease. Dr. Sternberg received his Ph.D. from the University of Maryland in Biochemistry in 1982.
Judith Segall , Vice President of Administration and Corporate Secretary
Judith Segall is our Vice President of Administration and Corporate Secretary, and has served on the Board of Directors from 1990 trhrough 1994 , and from 1995 through the present date. She was a cofounder of BioTime in 1990. Ms. Segall received a B.S. in Nutrition and Clinical Dietetics from the University of California at Berkeley in 1989.

News & Analysis